LA
JOLLA, Calif., Feb. 3, 2025
/PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer,
will present at the Oppenheimer 35th Annual Healthcare
Life Sciences Conference on Wednesday,
February 12, 2025, at 8:00 a.m.
ET.
A live webcast of the presentation can be accessed in the
"Upcoming Events" section of CalciMedica's IR website at
https://ir.calcimedica.com/. A replay of the webcast will be
archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved therapies. CalciMedica's lead
product candidate Auxora™ has demonstrated positive and
consistent clinical results in multiple completed efficacy clinical
trials. CalciMedica has announced data for a Phase
2b trial (called CARPO
– NCT04681066) in patients with acute pancreatitis (AP) and
accompanying systemic inflammatory response syndrome (SIRS). The
Company has also completed a Phase 2 trial (called CARDEA
– NCT04345614) in patients with COVID pneumonia. The Company
is currently conducting a Phase 2 trial (called KOURAGE
– NCT06374797) in patients with acute kidney disease (AKI)
with associated acute hypoxemic respiratory failure (AHRF) with
data expected in 2025 and continuing to support the ongoing Phase
1/2 trial (called CRSPA – NCT04195347) in pediatric patients
with asparaginase-induced pancreatic toxicity (AIPT) with data
expected in 2025. CalciMedica was founded by scientists
from Torrey Pines Therapeutics and the Harvard CBR Institute
for Biomedical Research, and is headquartered in La Jolla,
CA. For more information, please
visit www.calcimedica.com.
Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366737.html
SOURCE CalciMedica, Inc.
